Skip to main content
ConductScienceScienceDex

Juan Fernando Vera

NIH Rank #2374
Unclaimed recordClaim profile
  • R01 Holder
  • Early Career

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID 9545556Search this ID in NIH RePORTER
ScienceDex PI coverage
FY2024 through FY2025Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.

NIH Funding · FY2024

Linked Award Amount
$3.2M
Full award amounts, FY2024
Award Records
5
Records listing this PI
Award-Linked Rank
#2,374
By linked amount among FY2024 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for Juan Fernando Vera. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2024 NIH portfolio memberships

No institute-level portfolio release is available for this scientist and fiscal year yet. Existing award history remains unchanged above.

Researcher-associated datasets

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Award-linked funding history

Linked NIH award amounts and rank by fiscal year.

FY2024 award records by amount

NIH award records listing Juan Fernando Vera as a PI. Multi-PI records show the full award amount for context.

  • 1R44CA295168-01R44
    A Phase 1 Study of Patient-Derived Multi-Tumor Associated Antigen Specific T Cells (MT-601) Administered to Patients with Metastatic Pancreatic Cancer following frontline FOLFIRINOX
    Marker Therapeutics, Inc.
    $674.3K
    award amount
  • 1R44CA291521-01R44
    A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered to Patients with Relapsed Non-Hodgkin Lymphoma
    Marker Therapeutics, Inc.
    $665K
    award amount
  • 5R44CA285177-02R44
    Phase 2 clinical trial of a novel T cell therapy following bridging therapy with hypomethylating agents for relapsed AML patients post-stem cell transplant
    Marker Therapeutics, Inc.
    $664.8K
    award amount
  • 1R44CA287653-01A1R44
    Controlling Tumor Immune Escape in Pancreatic Cancer using a Dual T Cell Product Strategy
    Marker Therapeutics, Inc.
    $650.7K
    award amount
  • 5R01FD007272-02R01
    Efficacy of a Multi-Tumor-Associated Antigen-Specific T Cell Therapy in AML Patients following Allogeneic Stem Cell Transplant with Minimal Residual Disease
    Marker Therapeutics, Inc.
    $519.8K
    award amount

Award organization

Organizations that administered FY2024 awards listing Juan Fernando Vera as a PI.

FY2024 award administered by Marker Therapeutics, Inc. (TX).

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2024
    First NIH Award
    Marker Therapeutics, Inc.
  2. 2024
    $500K Cumulative Funding
  3. 2024
    $1M Cumulative Funding
  4. 2024
    $2M Cumulative Funding
  5. 2024
    Entered Top 50% Nationally
    Ranked #2374
  6. 2024
    Entered Top 25% Nationally
    Ranked #2374
  7. 2024
    R01 Grant Holder
  8. 2025
    $5M Cumulative Funding

Shared-award investigators

Other investigators listed on at least one of the same NIH award records as Juan Fernando Vera.

Brandon Smaglo
Marker Therapeutics, Inc.
2
shared awards
Laura S Angelo
Marker Therapeutics, Inc.
2
shared awards

Explore further

Find collaborators for Juan Fernando Vera

Search NIH-funded principal investigators by topic, department, or activity.

Open Find Collaborators →

Benchmark grant budgets

Compare median NIH grant budgets across departments, mechanisms, and years.

Open Grant Budget Benchmark →